Jianing Di

Amyloid-β ¹¹ C-PiB-PET imaging results from 2 randomized bapineuzumab phase 3 AD trials

Enchi Liu, Mark E. Schmidt, Richard Margolin et al. · Neurology · 2015 · 152 citations · Full text

Life Sciences, Neurology, Neuroscience +17

Translational Evaluation of JNJ-18038683, a 5-Hydroxytryptamine Type 7 Receptor Antagonist, on Rapid Eye Movement Sleep and in Major Depressive Disorder

Pascal Bonaventure, Christine Dugovic, Michelle Kramer et al. · Journal of Pharmacology and Experimental Therapeutics · 2012 · 86 citations

Medicine, Pharmacology, Psychiatry +16

Central Review of Amyloid-Related Imaging Abnormalities in Two Phase III Clinical Trials of Bapineuzumab in Mild-To-Moderate Alzheimer’s Disease Patients

Nzeera Ketter, H. Robert Brashear, Jennifer Bogert et al. · Journal of Alzheimer s Disease · 2017 · 85 citations · Full text

Medicine, Neurology, Neuroscience +17

Changes in Brain Volume with Bapineuzumab in Mild to Moderate Alzheimer’s Disease

Gerald Novak, Nick C. Fox, Shona Clegg et al. · Journal of Alzheimer s Disease · 2015 · 58 citations

Medicine, Neurology, Neuroscience +17

Clinical Evaluation of Amyloid-Related Imaging Abnormalities in Bapineuzumab Phase III Studies

H. Robert Brashear, Nzeera Ketter, Jennifer Bogert et al. · Journal of Alzheimer s Disease · 2018 · 38 citations

Medicine, Neurology, Radiology +17